Form 8-K - Current report:
SEC Accession No. 0001439222-25-000034
Filing Date
2025-05-01
Accepted
2025-05-01 06:32:25
Documents
15
Period of Report
2025-05-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K agio-20250501.htm   iXBRL 8-K 32913
2 EX-99.1 agio-050125xfyxex991earnin.htm EX-99.1 69228
6 GRAPHIC image_0.jpg GRAPHIC 58526
  Complete submission text file 0001439222-25-000034.txt   315738

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT agio-20250501.xsd EX-101.SCH 1764
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT agio-20250501_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT agio-20250501_pre.xml EX-101.PRE 12496
17 EXTRACTED XBRL INSTANCE DOCUMENT agio-20250501_htm.xml XML 2720
Mailing Address 88 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 88 SIDNEY STREET CAMBRIDGE MA 02139 617-649-8600
AGIOS PHARMACEUTICALS, INC. (Filer) CIK: 0001439222 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36014 | Film No.: 25899206
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)